DURECT Corporation (DRRX): Price and Financial Metrics
DURECT Corporation (DRRX)
Today's Latest Price: $1.71 USD
Updated Sep 30 4:00pm
Add DRRX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
DRRX Stock Summary
- With a one year PEG ratio of 186.98, Durect Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 83.31% of US stocks.
- Price to trailing twelve month operating cash flow for DRRX is currently 311.73, higher than 98.94% of US stocks with positive operating cash flow.
- As for revenue growth, note that DRRX's revenue has grown 153.13% over the past 12 months; that beats the revenue growth of 96.19% of US companies in our set.
- Stocks that are quantitatively similar to DRRX, based on their financial statements, market capitalization, and price volatility, are EXEL, ESPR, TNAV, CRUS, and SMCI.
- DRRX's SEC filings can be seen here. And to visit Durect Corp's official web site, go to www.durect.com.
DRRX Stock Price Chart Technical Analysis Charts
DRRX Price/Volume Stats
| Current price | $1.71 | 52-week high | $3.95 |
| Prev. close | $1.75 | 52-week low | $0.95 |
| Day low | $1.69 | Volume | 735,028 |
| Day high | $1.78 | Avg. volume | 1,426,292 |
| 50-day MA | $1.96 | Dividend yield | N/A |
| 200-day MA | $2.08 | Market Cap | 342.99M |
DURECT Corporation (DRRX) Company Bio
DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.
DRRX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $1.71 | $0.02 | -99% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Durect Corp. To summarize, we found that Durect Corp ranked in the 3th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for DRRX, they are:
- Its compound free cash flow growth rate, as measured over the past 2.24 years, is -0.04% -- higher than only 20.04% of stocks in our DCF forecasting set.
- As a business, Durect Corp experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than merely 0% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -99% |
| 1% | -99% |
| 2% | -99% |
| 3% | -99% |
| 4% | -99% |
| 5% | -99% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DRRX, try AGHC, AHPI, ALC, AMRN, and DRAD.
Loading social stream, please wait...